Dapagliflozin approved in EU for treatment of symptomatic heart failure with reduced ejection fraction (HFrEF)

Dapagliflozin has been approved for treatment of adult patients with and without diabetes, based on results from the DAPA-HF phase III trial, which demonstrated that addition of dapagliflozin to standard of care, reduced the risk of the composite outcome versus placebo by 26%.

Source:

PharmaTimes